| AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript |
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to AVITA Medical First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-09 01:50:59 |
Czytaj oryginał (ang.) |
| AVITA Medical Reports First Quarter 2025 Financial Results |
VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-08 20:03:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Announce First Quarter 2025 Financial Results |
VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. |
globenewswire.com |
2025-04-17 20:05:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 |
VALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona. |
globenewswire.com |
2025-04-09 20:05:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity |
VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. |
globenewswire.com |
2025-04-03 20:03:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific |
AVITA Medical announces new manufacturing agreement and amended distribution agreement with Stedical Scientific to further commercialization of PermeaDerm. |
globenewswire.com |
2025-03-17 18:05:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference |
AVITA Medical announced that Jim Corbett, CEO, will present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. Eastern Time. |
globenewswire.com |
2025-02-26 19:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know |
The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-02-20 12:55:30 |
Czytaj oryginał (ang.) |
| After Sales Rebound In January, AVITA Is Set Up For A Monster Year |
After Sales Rebound In January, AVITA Is Set Up For A Monster Year |
seekingalpha.com |
2025-02-18 14:01:26 |
Czytaj oryginał (ang.) |
| AVITA Medical to Host Investor Webinar Briefing |
AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on February 18, 2025 at 2:00PM PT. |
globenewswire.com |
2025-02-14 11:15:00 |
Czytaj oryginał (ang.) |
| AVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call Transcript |
AVITA Medical, Inc. (NASDAQ:RCEL ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-13 23:33:28 |
Czytaj oryginał (ang.) |
| AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results |
VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-13 18:01:00 |
Czytaj oryginał (ang.) |
| Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish |
AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance. |
seekingalpha.com |
2025-01-13 00:52:18 |
Czytaj oryginał (ang.) |
| AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini |
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini |
seekingalpha.com |
2025-01-10 20:28:56 |
Czytaj oryginał (ang.) |
| Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals |
On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024. |
benzinga.com |
2025-01-08 15:06:05 |
Czytaj oryginał (ang.) |
| Avita Medical price target lowered to $14 from $20 at Lake Street |
Lake Street analyst Brooks O'Neil lowered the firm's price target on Avita Medical to $14 from $20 and keeps a Buy rating on the shares after the company announced preliminary Q4 commercial revenue that was below the firm's estimate and consensus and management lowered the expected FY24 revenue outlook. The company also provided initial FY25 revenue guidance that was below the firm's previous revenue estimate, which Lake Street calls "disappointing." However, with shares off nearly 22% in the after hours, the firm is maintaining a Buy rating as it continues to think this is a significant year for Avita, the analyst added. |
https://thefly.com |
2025-01-08 11:00:03 |
Czytaj oryginał (ang.) |
| AVITA Medical, Quantum Computing And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Wednesday. |
benzinga.com |
2025-01-08 10:14:03 |
Czytaj oryginał (ang.) |
| AVITA Medical's shares sink 19% after another forecast cut |
AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target. |
reuters.com |
2025-01-08 00:12:07 |
Czytaj oryginał (ang.) |
| AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance |
AVITA Medical expects fourth quarter 2024 commercial revenue of approximately $18.4 million, reflecting growth of around 30% over the same period in 2023. |
globenewswire.com |
2025-01-07 18:35:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Just Tripled Its TAM In The Burn Market |
AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven by Q3 2025 has increased. The transition to RECELL GO has been highly successful, with 75% of the US sales base switching from the manual version. This is driving increased utilization. The total addressable market for AVITA's new ecosystem of products has expanded significantly, with the burning market TAM increasing from $450 million to $1.5 billion. |
seekingalpha.com |
2025-01-02 13:26:51 |
Czytaj oryginał (ang.) |
| AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds |
VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini. |
globenewswire.com |
2024-12-23 18:02:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market |
New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical's addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Cohealyx™, a new collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. |
globenewswire.com |
2024-12-19 19:05:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. |
globenewswire.com |
2024-12-18 18:08:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference |
VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time. |
globenewswire.com |
2024-11-25 18:02:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand |
VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care management and skin restoration, today announced it has entered into an exclusive distribution agreement with Revolution Surgical Pty Ltd. |
globenewswire.com |
2024-11-12 18:03:00 |
Czytaj oryginał (ang.) |
| AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript |
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Ross Osborne - Cantor Fitzgerald Eric Anderson - TD Cowen John Hester - Bell Potter Chris Kallos - MST Access Operator Good day and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-09 08:39:04 |
Czytaj oryginał (ang.) |
| AVITA Medical to Host Investor Webinar Briefing |
VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on November 12, 2024, at 2:00 p.m. |
globenewswire.com |
2024-11-08 11:00:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Reports Third Quarter Financial Results |
VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-07 18:03:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Announce Third Quarter 2024 Financial Results |
AVITA Medical announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on November 7, 2024. |
globenewswire.com |
2024-10-10 21:15:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Headed For Its Most Important Report, I'm Extremely Bullish |
AVITA Medical's RECELL GO offers superior wound healing with less donor skin required, reducing scarring and infection risk. It has no direct competition. RECELL GO streamlines the skin grafting process, saving time and money. New products like PermeaDerm and Cohealyx offer additional growth opportunities. Despite the Q1 sales hiccup & high operating losses, AVITA's underlying technology still has promise. The stock should rally if the Q3 sales target is met & operating margins improve. |
seekingalpha.com |
2024-10-02 17:07:15 |
Czytaj oryginał (ang.) |
| AVITA Medical to Present at 2024 Cantor Global Healthcare Conference |
VALENCIA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O'Toole, Chief Financial Officer, will present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. |
globenewswire.com |
2024-09-12 20:05:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Participate in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference |
VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that management will participate in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024. |
globenewswire.com |
2024-09-10 20:03:00 |
Czytaj oryginał (ang.) |
| AVITA Medical: New Products, Same Old Cash Burn (Rating Downgrade) |
RECELL GO's launch increased SG&A expenses, contributing to AVITA Medical, Inc.'s higher net losses in Q2 2024. Despite lowering its 2024 revenue guidance, AVITA Medical still anticipates significant year-over-year growth of 37-41%. AVITA Medical's cash runway is approximately nine months, with $54.1 million in cash and securities available as of June 30, 2024. |
seekingalpha.com |
2024-08-27 20:39:33 |
Czytaj oryginał (ang.) |
| AVITA Medical, Inc. (RCEL) Q2 2024 Earnings Call Transcript |
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Joshua Jennings - TD Cowen Aaron Wukmir - Lake Street Capital Market Ross Osborne - Cantor Fitzgerald Lyanne Harrison - Bank of America Operator Good day and thank you for standing by. Welcome to the AVITA Medical Second Quarter Conference Call. |
seekingalpha.com |
2024-08-09 10:01:04 |
Czytaj oryginał (ang.) |
| AVITA Medical to Host Investor Webinar Briefing |
VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on August 13, 2024, at 4:00 p.m. |
globenewswire.com |
2024-08-08 23:00:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Reports Second Quarter Financial Results |
AVITA Medical today reported second-quarter commercial revenue of $15.1 million, reflecting growth of over 29% over the same period in the prior year. |
globenewswire.com |
2024-08-08 20:04:00 |
Czytaj oryginał (ang.) |
| AVITA Medical to Announce Second Quarter 2024 Financial Results |
VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Thursday, August 8, 2024. |
globenewswire.com |
2024-07-11 20:10:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary |
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. |
globenewswire.com |
2024-07-01 20:05:00 |
Czytaj oryginał (ang.) |
| AVITA Medical Achieves Milestone with First Case Using RECELL GO |
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. |
globenewswire.com |
2024-06-05 20:25:00 |
Czytaj oryginał (ang.) |